Latest revenue
$0
as of 2025-09-30
Latest net income
$-529.9K
as of 2025-09-30
Net margin
—
as of 2025-09-30
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $624.5K
- Enterprise value
- $624.5K
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.03
- 52-wk low
- $0.00
- Beta
- —
- Shares out
- 567.7M
5-year trend
What this company does
ITEM 1. BUSINESS The following description of our business contains forward-looking statements relating to future events or our future financial or operating performance that involve risks and uncertainties, as set forth above under “Special Note Regarding Forward-Looking Statements.” Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors described in the Annual Report, including those set forth above in the Special Cautionary Note Regarding Forward-Looking Statements or under the heading “Risk Factors” or elsewhere in this Annual Report. Business Overview Aibotics, Inc. promotes the study of psychedelics for the…
AI summary unavailable — showing raw filing excerpt
Generated from AIBT's filing dated 2026-04-15
Key risks
ITEM 1A. RISK FACTORS We are not required to provide the information called for by this item.
AI summary unavailable — showing raw filing excerpt
Generated from AIBT's filing dated 2026-04-15
Profitability
Gross margin
100.0%
Operating margin
-84501.7%
Net margin
-101500.3%
Return on equity
56.0%
2.8%Return on assets
-253.3%
99.7%Leverage
Debt / equity
-1.22×
14.6%Debt / assets
552.8%
66.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | $0 | — | $-608.3K | -23.8% | — |
Q3 2025 2025-09-30 | $0 | — | $-529.9K | -15.2% | — |
Q2 2025 2025-06-30 | $0 | — | $-486.1K | -3.3% | — |
Q1 2025 2025-03-31 | $2.2K | — | $-591.4K | -38.8% | -27091.0% |
Q4 2024 2024-12-31 | $0 | — | $-491.5K | — | — |
Q3 2024 2024-09-30 | $0 | — | $-460.1K | -49.1% | — |
Q2 2024 2024-06-30 | $0 | — | $-470.7K | -68.9% | — |
Q1 2024 2024-03-31 | $0 | — | $-425.9K | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Medicinal Chemicals & Botanical Products · SIC 2833
Your notes
Keep private notes on AIBT — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AIBT
No institutional holdings on file for AIBT yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once AIBT's latest filing finishes processing.